NGNE Neurogene Inc.
$26.99▲ +14.66%
Healthcare
Other
After hours
$28.00▲ +3.74%
Oct 27, 4:03 PM ET
Volume 484.8K
Avg Volume (10D) 361.8K
Key Metrics & Fundamentals
Market Cap
$540.11M
P/E Ratio
–
Div Yield
0.00%
52W Range
15.93 - 43.66
% vs 50 MA
-13.66%
% vs 200 MA
-2.38%
RSI-14
50.6
MACD Histogram
+0.5100
Beta (1Y vs SPY)
1.52
Free Cash Flow
-$24.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$33.67M
COGS
–
Operating Exp
$36.67M
Operating Income
-$36.67M
EBIT
-$36.67M
Pretax Income
-$34.49M
Net Income
-$34.49M
EPS (Diluted)
-1.53
Price & Volume History
Loading chart…
Recent News
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Business Wire · Oct 27, 2026 7:30 AM ET
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Business Wire · Oct 20, 2026 7:30 AM ET
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Zacks · Oct 13, 2026 9:01 AM ET
JPMorgan Initiates Neurogene at Overweight With $60 Price Target
MT Newswires · Oct 8, 2026 7:29 AM ET
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 5, 2026 4:01 PM ET
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 8, 2026 7:30 AM ET
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Sep 4, 2026 4:01 PM ET
Neurogene: Q2 Earnings Snapshot
Associated Press · Aug 11, 2026 7:36 AM ET
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Business Wire · Aug 11, 2026 7:30 AM ET
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Aug 4, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NGNE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.